Detalhe da pesquisa
1.
OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
Mol Cell
; 73(1): 7-21.e7, 2019 01 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30472188
2.
lncRNA BREA2 promotes metastasis by disrupting the WWP2-mediated ubiquitination of Notch1.
Proc Natl Acad Sci U S A
; 120(8): e2206694120, 2023 02 21.
Artigo
Inglês
| MEDLINE | ID: mdl-36795754
3.
Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
Cancer
; 130(S8): 1378-1391, 2024 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37950749
4.
Deep Learning of Multimodal Ultrasound: Stratifying the Response to Neoadjuvant Chemotherapy in Breast Cancer Before Treatment.
Oncologist
; 29(2): e187-e197, 2024 Feb 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37669223
5.
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
BMC Med
; 20(1): 498, 2022 12 27.
Artigo
Inglês
| MEDLINE | ID: mdl-36575513
6.
Overexpression of GPX3, a potential biomarker for diagnosis and prognosis of breast cancer, inhibits progression of breast cancer cells in vitro.
Cancer Cell Int
; 20: 378, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32782436
7.
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population.
BMC Cancer
; 20(1): 255, 2020 Mar 29.
Artigo
Inglês
| MEDLINE | ID: mdl-32223744
8.
Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
Biochem Biophys Res Commun
; 503(3): 1605-1609, 2018 09 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30072097
9.
Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells.
Tumour Biol
; 37(8): 10861-70, 2016 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-26883251
10.
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Health Qual Life Outcomes
; 14: 51, 2016 Mar 24.
Artigo
Inglês
| MEDLINE | ID: mdl-27009092
11.
N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation.
Cell Physiol Biochem
; 36(6): 2494-503, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26279450
12.
Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.
Exp Cell Res
; 319(20): 3140-9, 2013 Dec 10.
Artigo
Inglês
| MEDLINE | ID: mdl-24012960
13.
The US2 protein is involved in the penetration and cell-to-cell spreading of DEV in vitro.
J Basic Microbiol
; 54(9): 1005-11, 2014 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-23828455
14.
Prognostic value of EIF5A2 in solid tumors: A meta-analysis and bioinformatics analysis.
Open Med (Wars)
; 19(1): 20240962, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38770178
15.
Patient preferences and willingness to pay for central venous access devices in breast cancer: A multicenter discrete choice experiment.
Int J Nurs Stud
; 152: 104695, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38301304
16.
A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012).
Front Oncol
; 14: 1326385, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38800388
17.
Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
Breast
; 73: 103671, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38277714
18.
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.
Nat Med
; 30(1): 249-256, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38191615
19.
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
J Clin Oncol
; 42(11): 1288-1300, 2024 Apr 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38301187
20.
Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.
Mod Pathol
; 26(1): 79-86, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-22918168